The company has recorded zero revenue for five consecutive quarters while sustaining $34.3 million in SG&A expenses during 2026Q1, indicating a complete lack of traction for its new business model.
| Sales/Revenue | 0 | - | - | - | - | - | - |
| Revenue Growth % | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | - | - | - | - | - | - |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -938K | 0 | 40K | 18K | 229K | 242K | -550K |
| Gross Margin % | - | - | 100% | 100% | 80.07% | 54.88% | - |
| Gross Profit Growth % | - | -100% | 122.22% | -92.14% | -5.37% | 144% | - |
| Operating Expenses | 102.92M | 71.09M | 12.9M | 28.53M | 27.49M | 33.65M | 53.75M |
| OpEx % of Revenue | - | - | 32255% | 158500% | 9613.29% | 7631.07% | - |
| Selling, General & Admin | 98.83M | 67.53M | 11.63M | 23.08M | 21.38M | 27.85M | 40.5M |
| SG&A % of Revenue | - | - | 29072.5% | 128205.56% | 7475.52% | 6315.87% | - |
| Research & Development | 0 | - | - | - | - | - | - |
| R&D % of Revenue | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | - | - | - | - | - | - |
| Operating Income | -103.86M | -71.09M | -12.86M | -28.51M | -27.27M | -33.41M | -54.3M |
| Operating Margin % | - | - | -32155% | -158400% | -9533.22% | -7576.19% | - |
| Operating Income Growth % | - | -452.74% | 54.89% | -4.57% | 18.4% | 38.47% | - |
| EBITDA | -98.85M | -67.56M | -12.67M | -28.15M | -26.97M | -33.21M | -53.75M |
| EBITDA Margin % | - | - | -31685% | -156394.44% | -9430.77% | -7531.29% | - |
| EBITDA Growth % | -693.03% | -433.06% | 54.98% | -4.37% | 18.79% | 38.21% | - |
| D&A (Non-Cash Add-back) | 5M | 3.53M | 188K | 361K | 293K | 198K | 550K |
| EBIT | -505.41M | -462.42M | -12.61M | -28.51M | -27.27M | -33.41M | -59.14M |
| Net Interest Income | 12.2M | -1.59M | -11K | 9K | 3K | 2K | 45K |
| Interest Income | 26K | 0 | 0 | 9K | 3K | 2K | 45K |
| Interest Expense | -12.17M | 1.59M | 11K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - | - | - | - | - |
| Pretax Income | -508.47M | -464.01M | -10.34M | -28.69M | -27.26M | -32.86M | -59.14M |
| Pretax Margin % | - | - | -25847.5% | -159388.89% | -9532.17% | -7450.34% | - |
| Income Tax | -1.8M | -1.24M | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.35% | 0.27% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -506.66M | -462.77M | -10.33M | -29.04M | -27.05M | -31.92M | -52.22M |
| Net Margin % | - | - | -25825% | -161338.89% | -9458.74% | -7237.41% | - |
| Net Income Growth % | -4412.43% | -4379.91% | 64.43% | -7.35% | 15.24% | 38.88% | - |
| Net Income (Continuing) | -506.67M | -462.77M | -10.34M | -28.69M | -27.26M | -32.86M | -59.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 256K | 32K | 17K | 26K | -21K | 219K | 802K |
| EPS (Diluted) | -10.56 | -9.65 | -0.75 | -3.95 | -6.33 | -9.53 | -18.72 |
| EPS Growth % | -1175.17% | -1186.67% | 81.01% | 37.6% | 33.58% | 49.09% | - |
| EPS (Basic) | - | -9.65 | -0.75 | -3.95 | -6.33 | -9.53 | -18.72 |
| Diluted Shares Outstanding | 47.97M | 47.97M | 14.04M | 7.35M | 4.31M | 3.35M | 2.79M |
| Basic Shares Outstanding | 47.97M | 47.97M | 14.04M | 7.35M | 4.31M | 3.35M | 2.79M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Total lack of revenue
As reported in recent financial filings, Streamex Corp. has recorded zero revenue for five consecutive quarters, signaling a complete cessation of legacy operations and a total lack of traction for its new fintech business model following the recent merger and corporate rebranding from BioSig Technologies.
The transition to a tokenization-focused model has yet to yield any measurable top-line results, rendering the company effectively pre-revenue. Investors should monitor whether the firm can establish any meaningful transaction volume, as the current trajectory suggests a complete absence of market adoption for its exchange infrastructure.
Based on the company's latest income statement, SG&A expenses reached $34.3 million in 2026Q1, highlighting a significant disconnect between the firm's aggressive operational spending and its inability to generate any offsetting revenue streams since the pivot to the Streamex Exchange platform was officially initiated.
The high level of administrative and professional fees suggests a heavy reliance on external consultants or legal support to navigate the regulatory landscape. This cost structure appears unsustainable without a rapid infusion of transaction-based income, as the current burn rate continues to erode the company's limited cash reserves.
According to historical income statements, the company reported a massive $424 million net loss in 2025Q4, which was heavily influenced by $55 million in stock-based compensation, suggesting that equity dilution remains a primary mechanism for funding operations rather than organic cash flow from core business activities.
The presence of significant non-operating items and large stock-based compensation charges complicates the assessment of true operational performance. Analysts should remain skeptical of the reported bottom line, as it appears to be heavily distorted by accounting adjustments and legacy restructuring costs rather than sustainable profitability.
As indicated by the company's recent SEC filings, the shift from medical technology to gold-backed tokenization lacks a proven track record, raising concerns that the current valuation is based on speculative option value rather than the tangible operational success of its newly integrated exchange infrastructure.
Short-sellers may focus on the company's history of value destruction under the previous BioSig entity as a proxy for potential future execution failures. The lack of a clear path to profitability, combined with the competitive pressure from established RWA providers, suggests that the current business model may face significant headwinds.
Quick answers to the most common questions about buying STEX stock.
Streamex Corp. (STEX) reported a net loss of $462.8M for the fiscal year ending 2025.